Table 3. Comparisons of significant gene alteration frequency of GEPNEC and local adenocarcinoma patients.

Gene	% (n/N)		OR (95% CI)	P	FDR
	GEPNEC vs. Adenocarcinoma
GEPNEC, gastroenteropancreatic neuroendocrine carcinoma; OR, odds ratio; 95% CI, 95% confidence interval; FDR, false discovery rate.
RB1 (mutation)	31.3 (31/99)	7.9 (8/101)	6.12 (2.65−16.00)	<0.001	<0.001
KRAS (mutation)	17.2 (17/99)	44.6 (45/101)	0.26 (0.13−0.49)	<0.001	<0.001
PIK3CA (mutation)	2.0 (2/99)	10.9 (11/101)	0.20 (0.04−0.80)	0.018	0.036
RNF43 (mutation)	2.0 (2/99)	9.9 (10/101)	0.23 (0.04−0.92)	0.033	0.053
ATM (mutation)	6.1 (6/99)	15.8 (16/101)	0.37 (0.13−0.96)	0.040	0.053
APC (mutation)	16.2 (16/99)	41.6 (42/101)	0.53 (0.29−0.96)	0.011	0.029
SMAD4 (mutation)	7.1 (7/99)	13.9 (14/101)	0.37 (0.12−1.00)	0.166	0.166
ARID1A (mutation)	8.1 (8/99)	17.8 (18/101)	0.41 (0.16−0.98)	0.057	0.065